Navigation Links
Genoa Pharmaceuticals announces $1.2M Financing
Date:11/8/2012

SAN DIEGO, Nov. 8, 2012 /PRNewswire/ -- Genoa Pharmaceuticals, a biotechnology company developing novel therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF), announced today the completion of a $1.2M financing. Funds from the financing will be used to advance its lead program, GP-101 (aerosol pirfenidone). IPF is a fatal lung disease caused by both genetic and environmental factors resulting in progressive lung scarring and characterized by reduced exercise capacity and chronic cough. IPF affects approximately 200,000 Americans and 135,000 Europeans.

Genoa was founded by Mark Surber, Ph.D., an aerosol development expert formerly with Mpex and Aires Pharmaceuticals. Dr. Surber serves as Genoa's President and Chief Scientific Officer. "IPF is a very serious disease with only 20% of patients surviving five years," said Dr. Surber. "Currently, there are no U.S. approved drugs, leaving lung transplant as the only option to extend life. Genoa's approach could be a significant advancement to treat patients with this devastating disease and we are excited about the opportunity to progress GP-101 into development."

Outside the United States, only oral pirfenidone is approved for the treatment of IPF. Sold by InterMune in Europe and Shionogi in Japan, this product has shown promise to extend life. However, the oral drug has been associated with gastrointestinal side effects that limit dosing and challenge patient compliance. To address this unmet need, Genoa has created GP-101 as a proprietary aerosol pirfenidone formulation for direct inhalation delivery to the lung. Compared to the oral medicine, inhaled GP-101 delivers an increased pirfenidone lung dose with improved pharmacokinetic parameters. As inhalation delivers more pirfenidone directly to the lung with reduced gastrointestinal exposure, inhaled GP-101 has the potential to improve the efficacy and safety profile of pirfenidone.

"We are pleased to have raised this initial seed financing," said Michael J. Kamdar, Genoa's Co-Founder and Chief Business Officer. "This financing will allow us to advance GP-101 to a key inflection point for prospective partners and investors by early 2013."

About Genoa Pharmaceuticals

Genoa Pharmaceuticals is committed to developing improved therapies for the treatment of Idiopathic Pulmonary Fibrosis. Based in San Diego, Genoa's lead program GP-101 (aerosol pirfenidone) is advancing towards the clinic for the treatment of IPF. Learn more at www.genoapharma.com


'/>"/>
SOURCE Genoa Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals Reports 2012 Third Quarter Financial Results
2. Arisaph Pharmaceuticals Reports Positive Results From Two Safety Clinical Trials For Its Niacin Analog (ARI-3037MO)
3. Oramed Pharmaceuticals to Present at the 12th Annual Diabetes Technology Society Meeting in Bethesda, MD, Nov 8-10, 2012
4. Optimer Pharmaceuticals to Present at November 2012 Investor Conferences
5. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
6. Isis Pharmaceuticals To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
7. Vanda Pharmaceuticals Reports Third Quarter 2012 Results
8. Radiopharmaceuticals and Contrast Media: Frost & Sullivan Predicts Market Growth in Europe
9. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
10. Enanta Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
11. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Calif. , Feb. 4, 2016  Edwards Lifesciences ... patient-focused innovations for structural heart disease and critical care ... accelerated share repurchase (ASR) agreement with Morgan Stanley & ... stock.  This repurchase is part of the Company,s previously ... the Company,s common stock.  --> ...
(Date:2/4/2016)... Feb. 4, 2016 Worldwide Radiology Oncology ... growth as next generation systems provide a way ... for cancer surgery. New systems pinpoint the delivery ... has been such a problem previously, limiting the ... robots take cancer surgery far beyond what has ...
(Date:2/4/2016)... Calif. , Feb. 4, 2016  SciClone ... today announced it has entered into a settlement ... Commission (SEC) fully resolving the SEC,s investigation into ... (FCPA).  Under the terms of the settlement agreement, ... $12.8 million, including disgorgement, pre-judgment interest and a ...
Breaking Medicine Technology:
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... and setting the stage for new clinical and scientific initiatives have all marked ... after she was appointed President and CEO of the nation’s oldest cancer center, ...
(Date:2/5/2016)... ... 05, 2016 , ... Looking for a last-minute Valentine’s Day gift for the ... toes. Foot massage, whether administered by a professional masseuse or a loved one, can ... Board of Multiple Specialties in Podiatry (ABMSP) has taken the upcoming Valentine’s Day ...
(Date:2/5/2016)... ... , ... US Sports Camps , official operators of Nike Yoga Camps, ... yoga training. ChildLight Yoga Studio is centrally situated in the picturesque New England city ... Studio founder Lisa Flynn expresses her excitement, “We are thrilled to be partnering with ...
(Date:2/5/2016)... ... 05, 2016 , ... Give To Cure today announced that it ... to Give To Cure’s campaign that is crowdfunding clinical trials to help find cures ... payments through a smart device. In 2015 alone, Venmo processed $7.5 billion in transactions ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Justin Scott and Dr. ... Annual No Cost Dental Day to individuals in need. The event is scheduled to ... No Cost Dental Day is to provide dental care to community members in need. ...
Breaking Medicine News(10 mins):